Caël B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S, Poussard M, Godet Y, Angelot-Delettre F, Barisien C, Bésiers C, Adotevi O, Pouthier F, Garnache-Ottou F, Bôle-Richard E

Cancers (Basel). 2022 06 28;14(13):

Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells.

Marton C, Mercier-Letondal P, Loyon R, Adotévi O, Borg C, Galaine J, Godet Y

Cancer Gene Ther. 2021 Oct 13;:

An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.

Marton C, Mercier-Letondal P, Galaine J, Godet Y

Cell Immunol. 2021 Feb 23;363:104314

Validation of a method evaluating T cell metabolic potential in compliance with ICH Q2 (R1).

Mercier-Letondal P, Marton C, Godet Y, Galaine J

J Transl Med. 2021 Jan 6;19(1):21

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y

Int. J. Cancer. 2019 Aug 9;:

Circulating NKp46 Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O

Oncoimmunology. 2019 ;8(2):e1527498

Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Loyon R, Jary M, Salomé B, Gomez-Cadena A, Galaine J, Kroemer M, Romero P, Trabanelli S, Adotévi O, Borg C, Jandus C

Front Immunol. 2019 ;10:2121

Biologie, concepts et principes des CAR-T cells

Rubio MT, Galaine J, Borg C, Daguindau É

Bull Cancer. 2018 Dec;105 Suppl 2:S135-S146

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y

Oncotarget. 2018 Oct 23;9(83):35394-35407

Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y

Hum. Gene Ther.. 2018 Aug 23;:

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C

Oncoimmunology. 2018 ;7(5):e1424673

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E

Oncoimmunology. 2018 ;7(5):e1423170

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C

Oncoimmunology. 2018 ;7(4):e1412030

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A0201/DRB10101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Marie Joseph EL, Asgarova A, Borg C, Saati TA, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O

Oncotarget. 2017 Apr;:

Galaine J, Godet Y, Adotévi O

Bull Cancer. 2016 Nov;103 Suppl 1:S127-S131

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O

J. Immunol.. 2016 Sep;197(5):1597-608

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C

J. Immunol.. 2016 Jul;197(1):85-96

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O

Oncoimmunology. 2016 May;5(5):e1137416

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C

Hum Vaccin Immunother. 2013 May;9(5):1073-7

Dr GALAINE Jeanne

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Projets

Murine models of Allogenic T Cell therapy (MAllo)

Génération de lymphocytes T anti-tumeur génétiquement modifiés à partir du sang placentaire : intérêt pour l’optimisation du transfert adoptif

Publications

Characterization of atypical T cells generated during expansion process for T cell-based adoptive immunotherapy.

Production of functional plasmacytoid dendritic cells-targeted CAR-T cells from patients with immune-mediated inflammatory diseases.

Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.